Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Holding ANAB?
Track your performance easily
ANAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.51 - $41.31
Previous Close$14.6
Volume286.08K
Average Volume (3M)601.87K
Market Cap
$473.47M
Enterprise Value$30.64M
Total Cash (Recent Filing)$430.12M
Total Debt (Recent Filing)$16.49M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Feb 27, 2025EPS Estimate
-$1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.07
Shares Outstanding30,428,682
10 Day Avg. Volume579,753
30 Day Avg. Volume601,871
Standard Deviation0.21
R-Squared0.00001
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)5.27
Price to Sales (P/S)7.77
Price to Cash Flow (P/CF)-11.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.54
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$37.36Price Target Upside140.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
AnaptysBio News
Bulls Say, Bears Say
Bulls Say
Financial PositioningAnaptysBio is financially positioned to advance its pipeline with anticipated year-end cash of approximately $415 million, sufficient to extend its runway through year-end 2027.
Market PotentialAnaptysBio is an emerging clinical-stage company in the inflammatory space, with a wholly owned asset entering mid-stage development, providing validation for the mechanistic approach within a very large addressable market.
Safety And EfficacyRosnilimab showed favorable safety and tolerability in a phase 1 study with no serious adverse events or infection signals.
Bears Say
Clinical Trial OutcomeANB032 Phase 2b AD study does not meet primary or secondary endpoints; further development discontinued.
Market SentimentSentiment on ANAB shares is clearly negative, post ANB032 failure / discontinuation in atopic dermatitis and Lilly’s peresolimab discontinuation.
Program DiscontinuationThe price target for AnaptysBio's stock has been lowered from $45 to $32 following the discontinuation of the BTLA agonist program.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.51 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
Currently, no data Available
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Feb 27, 2025 which is in 52 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Nov 05, 2024. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.647 by $0.507.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -$1.62.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 30,428,682 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.647. Following the earnings report the stock price went up 11.72%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Among the largest hedge funds holding AnaptysBio Inc’s share is Woodline Partners LP. It holds AnaptysBio Inc’s shares valued at 15M.
---
AnaptysBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.36 (140.10% Upside)
$37.36 (140.10% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 399.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 18.5%
Last 30 Days ▼ 18.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.09%
12-Months-Change
Fundamentals
Return on Equity
-161.81%
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
ANAB Stock 12 Month Forecast
Average Price Target
$37.36
▲(140.10% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
-34.44%
reiterated a buy rating 19 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of -34.44% per trade.
---